Amgen (AMGN): Solid Results But Concerns Over Increasing Competition Demand a Neutral Rating - Baird

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/12/2026

1. HUM
2. SPCX
3. ALHC
4. PEP
5. T
6. TMUS
7. AXP
8. DAL
9. VZ
10. SPY

Go back to Amgen (AMGN): Solid Results But Concerns Over Increasing Competition Demand a Neutral Rating - Baird

Leerink Partners Remains Sidelined on Amgen (AMGN) Following 2Q

July 28, 2016 7:18 AM EDT

Leerink Partners reiterated a Market Perform rating on Amgen (NASDAQ: AMGN), and raised the price target to $201.00 (from $186.00), following the company's 2Q earnings report. AMGN reported total revenues of $5.69bn, beating consensus by 3%. The company also reported an operating margin of 51% on expenses of $2.876bn, which was in-line with consensus.

Analyst Geoffrey C. Porges commented, "Amgen Reported Q2 Results Beating Consensus for Revenue by 2% and Beating by 3% on EPS. Total revenue of $5.69bn included $5.474bn in product sales that beat consensus by 3% and missed our estimate by -2%. As with the... More